{"id":3476,"date":"2024-05-21T10:47:07","date_gmt":"2024-05-21T07:47:07","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3476"},"modified":"2024-05-21T10:57:40","modified_gmt":"2024-05-21T07:57:40","slug":"astrazeneca-turkiyenin-klinik-calismalara-yaptigi-yatirim-1-milyar-tlyi-asti","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3476","title":{"rendered":"AstraZeneca T\u00fcrkiye\u2019nin Klinik \u00c7al\u0131\u015fmalara Yapt\u0131\u011f\u0131 Yat\u0131r\u0131m 1 Milyar TL\u2019yi A\u015ft\u0131!"},"content":{"rendered":"\n

T\u00fcrkiye\u2019de 2022 ve 2023 y\u0131llar\u0131nda en fazla klinik ara\u015ft\u0131rma ba\u015flatan \u015firket olan AstraZeneca\u2019n\u0131n 2020 y\u0131l\u0131ndan bu yana \u00fclkemizdeki klinik ara\u015ft\u0131rmalara yapt\u0131\u011f\u0131 yat\u0131r\u0131mlar 1 milyar TL\u2019nin \u00fczerine \u00e7\u0131kt\u0131.<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Klinik ara\u015ft\u0131rmalar, hastalar\u0131n ya\u015fam kalitesinin art\u0131r\u0131lmas\u0131, bilimsel \u00e7al\u0131\u015fmalar ve sa\u011fl\u0131k sistemlerinin geli\u015fmesi a\u00e7\u0131s\u0131ndan kritik bir rol oynuyor. Bu nedenle her y\u0131l 20 May\u0131s, D\u00fcnya Klinik Ara\u015ft\u0131rmalar G\u00fcn\u00fc olarak kutlan\u0131yor. Bundan 25 y\u0131l \u00f6nce insanl\u0131\u011f\u0131n kar\u015f\u0131 kar\u015f\u0131ya oldu\u011fu en b\u00fcy\u00fck sa\u011fl\u0131k sorunlar\u0131na \u00e7\u00f6z\u00fcm bulmak ve hastalar\u0131n ya\u015fam\u0131na de\u011fer katmak amac\u0131yla Astra ve Zeneca firmalar\u0131n\u0131n g\u00fc\u00e7lerini birle\u015ftirmesiyle ortaya \u00e7\u0131kan d\u00fcnyan\u0131n \u00f6nde gelen yenilik\u00e7i ila\u00e7 \u015firketlerinden biri olan AstraZeneca, T\u00fcrkiye\u2019de istikrarl\u0131 \u015fekilde klinik \u00e7al\u0131\u015fmalar\u0131n\u0131 ve bu alandaki yat\u0131r\u0131mlar\u0131n\u0131 s\u00fcrd\u00fcr\u00fcyor.  <\/p>\n\n\n\n

AstraZeneca\u2019n\u0131n \u00f6nde gelen dan\u0131\u015fmanl\u0131k \u015firketlerinden EY T\u00fcrkiye destekleri ile geride b\u0131rakt\u0131\u011f\u0131 \u00e7eyrek y\u00fczy\u0131l boyunca ila\u00e7 sekt\u00f6r\u00fcne ve \u00fclkemize yapt\u0131\u011f\u0131 etkiyi g\u00f6zler \u00f6n\u00fcne serdi\u011fi \u201cAstraZeneca\u2019n\u0131n T\u00fcrkiye\u2019ye Etkileri<\/a>\u201d Raporu\u2019na g\u00f6re AstraZeneca \u00fclkemizde 2022 ve 2023 y\u0131llar\u0131nda en fazla klinik ara\u015ft\u0131rma ba\u015flatan \u015firket olurken yakla\u015f\u0131k 100 ki\u015filik klinik ara\u015ft\u0131rma ekibiyle 90 aktif klinik ara\u015ft\u0131rma \u00e7al\u0131\u015fmas\u0131 y\u00fcr\u00fct\u00fcyor. AstraZeneca 2020 y\u0131l\u0131ndan bu yana klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131nda ciddi bir art\u0131\u015f ger\u00e7ekle\u015ftirdi ve toplam yat\u0131r\u0131m tutar\u0131n\u0131 da 1,1 milyar TL\u2019ye \u00e7\u0131kard\u0131. AstraZeneca\u2019n\u0131n \u00fclkemizde s\u00fcrd\u00fcrd\u00fc\u011f\u00fc klinik ara\u015ft\u0131rmalar\u0131n y\u00fczde 65’ini ise onkoloji alan\u0131ndaki \u00e7al\u0131\u015fmalar olu\u015fturuyor.<\/p>\n\n\n\n

\u201cSadece ge\u00e7en y\u0131l 500 milyon TL\u2019den fazla yat\u0131r\u0131m yapt\u0131k\u201d<\/strong><\/p>\n\n\n\n

Klinik ara\u015ft\u0131rmalara yap\u0131lan yat\u0131r\u0131mlar\u0131n artmas\u0131n\u0131n yat\u0131r\u0131m \u00e7eken \u00fclkelerde yenilik\u00e7i tedavi ve bilgiye eri\u015fimin h\u0131zlanmas\u0131na olanak sa\u011flad\u0131\u011f\u0131n\u0131 s\u00f6yleyen AstraZeneca T\u00fcrkiye \u00dclke Ba\u015fkan\u0131 Ecz. Serkan Bar\u0131\u015f<\/strong>, \u201cBiz de k\u00f6kl\u00fc deneyimimizden ald\u0131\u011f\u0131m\u0131z g\u00fc\u00e7 ile her y\u0131l istikrarl\u0131 bir \u015fekilde b\u00fcy\u00fcmemizi s\u00fcrd\u00fcr\u00fcrken T\u00fcrkiye\u2019de en fazla klinik ara\u015ft\u0131rma ba\u015flatan ila\u00e7 \u015firketi olarak sa\u011fl\u0131k politikas\u0131 \u00f6nceliklerine \u00f6nemli katk\u0131larda bulunuyoruz. 2023 y\u0131l\u0131nda 570 milyon TL klinik ara\u015ft\u0131rma yat\u0131r\u0131m\u0131 yapt\u0131k. Son d\u00f6rt y\u0131lda yapt\u0131\u011f\u0131m\u0131z yat\u0131r\u0131mlar 1 milyar TL\u2019yi a\u015ft\u0131. Di\u011fer yandan \u00fclkemizdeki aktif klinik ara\u015ft\u0131rmalar\u0131m\u0131z\u0131n b\u00fcy\u00fck b\u00f6l\u00fcm\u00fcn\u00fc onkoloji alan\u0131ndaki \u00e7al\u0131\u015fmalar\u0131m\u0131z olu\u015fturuyor. Bu sayede kanser gibi zorlu hastal\u0131klar\u0131n tedavisinde yeni geli\u015fmelerin takip edilebilmesine, hastalar\u0131n yenilik\u00e7i tedavilere erken eri\u015fimine ve daha iyi sa\u011fl\u0131k sonu\u00e7lar\u0131na ula\u015fmas\u0131na \u00f6nemli bir katk\u0131 sa\u011fl\u0131yoruz. Tedavi alanlar\u0131m\u0131zda en g\u00fcncel bilginin \u00fcretilmesine, klinik ara\u015ft\u0131rma \u00e7al\u0131\u015fmalar\u0131n\u0131 yayg\u0131nla\u015ft\u0131rarak sa\u011fl\u0131k i\u015f g\u00fcc\u00fc ve altyap\u0131s\u0131n\u0131n geli\u015fimine sa\u011flad\u0131\u011f\u0131m\u0131z katk\u0131dan gurur duyuyoruz\u201d dedi.<\/p>\n\n\n\n

\u201cT\u00fcrkiye\u2019nin klinik ara\u015ft\u0131rmalarda b\u00f6lgede lider olmas\u0131n\u0131 hedefliyoruz\u201d<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

AstraZeneca\u2019n\u0131n T\u00fcrkiye\u2019de en fazla say\u0131da klinik ara\u015ft\u0131rma y\u00fcr\u00fcten firmalar aras\u0131nda yer ald\u0131\u011f\u0131n\u0131 vurgulayan AstraZeneca T\u00fcrkiye Medikal Direkt\u00f6r\u00fc Dr. Deniz Ert\u00fcrk Erem <\/strong>ise \u015funlar\u0131 s\u00f6yledi: \u201cKlinik ara\u015ft\u0131rmalar alan\u0131nda \u00fclkemizde ilk s\u0131rada olmay\u0131 ve T\u00fcrkiye\u2019nin b\u00f6lgede lider konuma gelmesine katk\u0131 sa\u011flamay\u0131 ama\u00e7l\u0131yoruz. Son y\u0131llarda esasl\u0131 \u015fekilde artan klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131m\u0131z\u0131n yan\u0131 s\u0131ra kurumsal i\u015f birliklerimiz ile bu alandaki kararl\u0131l\u0131\u011f\u0131m\u0131z\u0131 da ortaya koyuyoruz. Nitekim 2022 ve 2023 y\u0131llar\u0131nda T\u00fcrkiye\u2019de en fazla yeni klinik ara\u015ft\u0131rma \u00e7al\u0131\u015fmas\u0131n\u0131 ba\u015flatan ila\u00e7 \u015firketi AstraZeneca olmu\u015ftur. \u00dcniversiteler ve hekim dernekleri ba\u015fta olmak \u00fczere \u00fclkemiz sa\u011fl\u0131k ekosisteminde klinik ara\u015ft\u0131rmalara pek \u00e7ok destekte bulunuyoruz. Abdurrahman Yurtaslan Ankara Onkoloji E\u011fitim ve Ara\u015ft\u0131rma Hastanesi ve Adana \u015eehir E\u011fitim ve Ara\u015ft\u0131rma Hastanesi ile ger\u00e7ekle\u015ftirdi\u011fimiz stratejik ortakl\u0131k ile klinik \u00e7al\u0131\u015fma say\u0131s\u0131n\u0131n art\u0131r\u0131lmas\u0131n\u0131 ve daha fazla hastan\u0131n klinik \u00e7al\u0131\u015fmalara d\u00e2hil edilerek yenilik\u00e7i tedavilere ula\u015fabilmesini hedefliyoruz. Ayr\u0131ca T\u00fcrkiye genelinde 38 ilde bulunan toplam 95 merkez ile i\u015f birli\u011fi yaparak ger\u00e7ek ya\u015fam verisi \u00fcretmek ve \u00fcretilmesine destek olmak \u00fczere de \u00e7al\u0131\u015fmalar yap\u0131yoruz. Son 5 y\u0131lda kalp yetersizli\u011fi, kronik b\u00f6brek hastal\u0131\u011f\u0131, ast\u0131m, akci\u011fer kanseri gibi pek \u00e7ok hastal\u0131k alan\u0131nda 20\u2019nin \u00fczerinde ger\u00e7ek ya\u015fam verisi yap\u0131lmas\u0131na katk\u0131da bulunduk.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

T\u00fcrkiye\u2019de 2022 ve 2023 y\u0131llar\u0131nda en fazla klinik ara\u015ft\u0131rma ba\u015flatan \u015firket olan AstraZeneca\u2019n\u0131n 2020 y\u0131l\u0131ndan bu yana \u00fclkemizdeki klinik ara\u015ft\u0131rmalara yapt\u0131\u011f\u0131 yat\u0131r\u0131mlar 1 milyar TL\u2019nin \u00fczerine \u00e7\u0131kt\u0131.<\/p>\n","protected":false},"author":1,"featured_media":3477,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3476"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3476"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3476\/revisions"}],"predecessor-version":[{"id":3493,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3476\/revisions\/3493"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3477"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}